| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BREAST.2003.08.004 |
| P698 | PubMed publication ID | 15019688 |
| P2093 | author name string | Ashley S | |
| Smith IE | |||
| Dowsett M | |||
| Hills M | |||
| Parton M | |||
| Lowe F | |||
| P433 | issue | 2 | |
| P921 | main subject | inflammation | Q101991 |
| P304 | page(s) | 97-103 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | The Breast | Q7719928 |
| P1476 | title | High incidence of HER-2 positivity in inflammatory breast cancer | |
| P478 | volume | 13 |
| Q36514752 | A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. |
| Q35829855 | Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration |
| Q37687382 | Biology and management of inflammatory breast cancer |
| Q36848095 | Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. |
| Q35052773 | Circulating tumor cells in newly diagnosed inflammatory breast cancer |
| Q40440921 | Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations |
| Q91595396 | Construction and Validation of Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Nonmetastatic Inflammatory Breast Cancer Patients Receiving Tri-Modality Therapy: A Population-Based Study |
| Q47836759 | Deciphering metabolic rewiring in breast cancer subtypes |
| Q28075322 | Developmental therapeutics for inflammatory breast cancer: Biology and translational directions |
| Q63366190 | Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early |
| Q46624267 | European oncologists' preferences for the management of breast cancer: case presentations and expert commentary |
| Q54281598 | Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study. |
| Q64255196 | Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression |
| Q59812798 | Inflammatory Breast Cancer: A Literature Review |
| Q63366138 | Inflammatory breast cancer biology: the tumour microenvironment is key |
| Q39980598 | Inflammatory breast cancer: A decade of experience |
| Q34753009 | Inflammatory breast cancer: the experience of Baylor University Medical Center at Dallas |
| Q37642758 | Inflammatory breast cancer: what are the treatment options? |
| Q27028128 | Inflammatory breast cancer: what we know and what we need to learn |
| Q35017523 | International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment |
| Q41110592 | Lymph node status in inflammatory breast cancer. |
| Q37495412 | Molecular targets for treatment of inflammatory breast cancer |
| Q90428103 | Nomogram for predicting cancer specific survival in inflammatory breast carcinoma: a SEER population-based study |
| Q43054038 | Novel targeted therapies in inflammatory breast cancer |
| Q27692623 | Primary systemic chemotherapy for inflammatory breast cancer |
| Q37205563 | Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry |
| Q36900976 | Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway |
Search more.